Opportunity Information: Apply for PA 16 173
Apply for PA 16 173
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Limited Competition: Tissue Chips for Rare Diseases (Admin Supp)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.350,.
- This funding opportunity was created on Apr 08, 2016 and posted on Apr 08, 2016.
- Applicants must submit their applications by Apr 22, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $100,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Limited Competition: Tissue Chips for Rare Diseases (Admin Supp) (PA 16-173) is an NIH discretionary grant opportunity designed as an administrative supplement, meaning it provides add-on funding to support extra work on projects that are already funded rather than funding brand-new, independent awards. The central goal is to help existing NIH Tissue Chip (TC) Program investigators and their institutions build and evaluate tissue chip or microphysiological system devices specifically tailored to rare diseases. A key feature of the opportunity is the expectation that this rare-disease-focused tissue chip work will be carried out in connection with the Rare Diseases Clinical Research Network (RDCRN), which is positioned to provide rare disease expertise, clinical context, and access to patient-oriented knowledge and resources.
This is a limited competition, so eligibility is not open to the general research community even though many organization types are listed as generally eligible NIH applicants. In practical terms, the announcement restricts applications to investigators and awardees already funded under the NIH Tissue Chip program mechanism described in RFA-RM-11-022, Integrated Microphysiological Systems for Drug Efficacy and Toxicity Testing in Human Health and Disease (UH2/UH3). The supplement is meant to extend or adapt existing tissue chip platforms toward modeling rare disease biology, enabling proof-of-concept development and testing that could make these platforms more relevant to rare disease research and, ultimately, therapeutic development and safety testing.
The activity area is health (CFDA 93.350), and the funding instrument is a grant administered by NIH (HHS-NIH11). The opportunity set an award ceiling of $100,000 per supplement, indicating a relatively targeted budget intended to accelerate a specific set of additional experiments or device refinements rather than to support a large multi-year expansion. The posting and creation dates were April 8, 2016, with an application due date (closing date) of April 22, 2016, reflecting a short turnaround that is typical of some administrative supplement announcements.
While the eligible applicant list includes a wide range of entities (federal recognized tribal governments and organizations, state and local governments, public and private higher education institutions, nonprofits with or without 501(c)(3) status, for-profit organizations, and small businesses), the practical gatekeeper for this particular announcement is being part of the NIH Tissue Chip Program cohort funded under the specified UH2/UH3 solicitation. The overall intent is to leverage ongoing tissue chip engineering and validation efforts and connect them with RDCRN rare disease communities, so that the resulting devices can better capture disease-specific mechanisms, improve the relevance of preclinical testing, and strengthen translational pathways for conditions that often lack robust laboratory models.
Frequently Asked Questions (FAQs)
What is the "Limited Competition: Tissue Chips for Rare Diseases (Admin Supp) (PA 16-173)" opportunity?
This is an NIH discretionary grant opportunity offered as an administrative supplement (add-on funding). It is intended to support additional work on projects that are already funded, rather than to create brand-new, stand-alone awards.
Is this funding for new, independent projects?
No. The opportunity is specifically described as an administrative supplement, which means the funding is meant to extend, adapt, or accelerate work tied to an existing NIH-funded project rather than support a new independent award.
What is the main purpose of this administrative supplement?
The central goal is to help existing NIH Tissue Chip (TC) Program investigators and their institutions build and evaluate tissue chip or microphysiological system devices tailored to rare diseases. The supplement is intended to enable proof-of-concept development and testing to make existing tissue chip platforms more relevant to rare disease research.
What kinds of technologies or platforms does this opportunity focus on?
The focus is on tissue chips and microphysiological system devices. The intent is to extend or adapt existing tissue chip platforms toward modeling rare disease biology and improving the relevance of preclinical testing (including drug efficacy and safety/toxicity testing).
Who is eligible to apply in practice?
Although the announcement lists many types of organizations as generally eligible NIH applicants, this is a limited competition. In practical terms, applications are restricted to investigators and awardees already funded under the NIH Tissue Chip program mechanism described in RFA-RM-11-022, Integrated Microphysiological Systems for Drug Efficacy and Toxicity Testing in Human Health and Disease (UH2/UH3).
Why is the competition described as "limited"?
It is limited because eligibility is not open to the general research community. The announcement restricts applications to a defined cohort: existing NIH Tissue Chip Program investigators funded under the specified UH2/UH3 solicitation (RFA-RM-11-022).
Does my organization type matter if I am not already part of the NIH Tissue Chip Program cohort?
Yes. Even though a wide range of entity types are listed as eligible (including universities, nonprofits, for-profits, small businesses, and certain government entities), the key gatekeeper for this opportunity is membership in the NIH Tissue Chip Program cohort funded under RFA-RM-11-022 (UH2/UH3). If you are not an eligible Tissue Chip awardee/investigator under that mechanism, this supplement is not practically available.
What role does the Rare Diseases Clinical Research Network (RDCRN) play?
A key feature of the opportunity is the expectation that rare-disease-focused tissue chip work will be carried out in connection with the RDCRN. The RDCRN is positioned to provide rare disease expertise, clinical context, and access to patient-oriented knowledge and resources.
Is collaboration with the RDCRN required or only encouraged?
Based on the opportunity description provided, there is an expectation that the work will be carried out in connection with the RDCRN, indicating that RDCRN involvement is a central element of the supplement's approach.
What is the funding instrument for this opportunity?
The funding instrument is a grant administered by NIH (HHS-NIH11), and it is provided as an administrative supplement to an existing award.
What is the maximum award amount?
The award ceiling is $100,000 per supplement.
What does the $100,000 ceiling imply about the scope of work?
The stated ceiling suggests the supplement is designed for a targeted set of additional experiments, device refinements, or proof-of-concept efforts to accelerate rare-disease-specific adaptations of existing tissue chip platforms, rather than supporting a large multi-year expansion.
What is the activity area and CFDA number?
The activity area is health, and the CFDA number listed is 93.350.
When was this opportunity posted and when were applications due?
The posting and creation dates were April 8, 2016. The application due date (closing date) was April 22, 2016.
What does the short application window indicate?
The short turnaround (from April 8 to April 22, 2016) aligns with how some administrative supplement announcements operate, where funding is intended to move quickly to support time-sensitive add-on work to existing projects.
What is the broader intended impact of rare-disease-focused tissue chips?
The intent is to leverage ongoing tissue chip engineering and validation efforts and connect them with RDCRN rare disease communities. The resulting devices are expected to better capture disease-specific mechanisms, improve the relevance of preclinical testing, and strengthen translational pathways for rare conditions that often lack robust laboratory models.
What prior NIH solicitation is specifically tied to eligibility?
Eligibility is tied to the NIH Tissue Chip program mechanism described in RFA-RM-11-022: Integrated Microphysiological Systems for Drug Efficacy and Toxicity Testing in Human Health and Disease (UH2/UH3).
Browse more opportunities from the same category: Health
Next opportunity: Limited Competition: Tissue Chips and Missing Organs (Admin Supp)
Previous opportunity: Exploratory Grants in Cancer Epidemiology and Genomics Research (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 173
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 173) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition: Tissue Chips and Missing Organs (Admin Supp) Apply for PA 16 178 Funding Number: PA 16 178 Agency: HHS-NIH11 Category: Health Funding Amount: $50,000 |
| Minority AIDS Initiative Continuum of Care Pilot (MAI-CoC) Syringe Services Programs (SSPs) (Short Title: MAI-CoC: SSP) Apply for SP 16 008 Funding Number: SP 16 008 Agency: HHS-SAMHS Category: Health Funding Amount: $82,500 |
| TRANSFORM/WASH Apply for RFA 663 16 000007 Funding Number: RFA 663 16 000007 Agency: USAID-ETH Category: Health Funding Amount: $24,000,000 |
| Tribal Management Grant Program Apply for HHS 2016 IHS TMD 0001 Funding Number: HHS 2016 IHS TMD 0001 Agency: HHS-IHS Category: Health Funding Amount: $100,000 |
| Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (R41/R42) Apply for PA 16 181 Funding Number: PA 16 181 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (R43/R44) Apply for PA 16 180 Funding Number: PA 16 180 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18) Apply for PAR 16 179 Funding Number: PAR 16 179 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Strategies for the Improvement of HIV Envelope Protein Expression and Yield (R41/R42) Apply for PA 16 182 Funding Number: PA 16 182 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Products to Support Applied Research Towards Zero Suicide Healthcare Systems (R43/R44) Apply for PAR 16 185 Funding Number: PAR 16 185 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Strategies for the Improvement of HIV Envelope Protein Expression and Yield (R43/R44) Apply for PA 16 184 Funding Number: PA 16 184 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| The USAID Global Health Challenge BAA Apply for BAA GLOBAL HEALTH 2016 Funding Number: BAA GLOBAL HEALTH 2016 Agency: USAID Category: Health Funding Amount: Case Dependent |
| Implementing Public Health Programs and Strengthening Public Health Capacity in Guatemala and Central American Apply for CDC RFA GH13 130604CONT16 Funding Number: CDC RFA GH13 130604CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Natural History Studies for Rare Disease Product Development: Orphan Products Research Project Grant (R01) Apply for RFA FD 16 043 Funding Number: RFA FD 16 043 Agency: HHS-FDA Category: Health Funding Amount: $400,000 |
| Health Informatics Governance and Data Analytics (HIGDA) Apply for RFA 615 16 000009 Funding Number: RFA 615 16 000009 Agency: USAID-KEN Category: Health Funding Amount: $17,000,000 |
| Enhanced Access to and Utilization of Quality Family Planning/Reproductive, Maternal, Newborn, Child and Adolescent Health (FP/RMNCAH) Services in Selected Counties and Sub-counties, Kenya – (AFYA FP/RMNCAH). Apply for RFA 615 16 000007 Funding Number: RFA 615 16 000007 Agency: USAID-KEN Category: Health Funding Amount: $64,500,000 |
| NHLBI TOPMed Program: Integrative Omics Approaches for Analysis of TOPMed Data (U01) Apply for RFA HL 17 011 Funding Number: RFA HL 17 011 Agency: HHS-NIH11 Category: Health Funding Amount: $400,000 |
| New Access Points Apply for HRSA 17 009 Funding Number: HRSA 17 009 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| HIV Pre-exposure Prophylaxis (PrEP) Implementation Science in CDC-funded Public Health Demonstration Projects (Admin Supp) Apply for PA 16 199 Funding Number: PA 16 199 Agency: HHS-NIH11 Category: Health Funding Amount: $175,000 |
| HUMAN RESOURCES FOR HEALTH (HRH) KENYA PROGRAM Apply for RFA 615 16 000008 Funding Number: RFA 615 16 000008 Agency: USAID-KEN Category: Health Funding Amount: $38,000,000 |
| County Measurements, Learning and Accountability Program (CMLAP) Apply for RFA 615 16 000010 Funding Number: RFA 615 16 000010 Agency: USAID-KEN Category: Health Funding Amount: $17,750,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 173", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.